Issue link: http://osercommunicationsgroup.uberflip.com/i/562613
C h a i n D r u g s t o r e D a i l y M o n d a y, A u g u s t 2 4 , 2 0 1 5 3 4 THE DIVACUP FROM DIVA INTERNATIONAL INC. Diva International Inc. believes that men- strual care products should provide women with assurances of health, securi- ty and convenience, while offering a more sustainable solution for both the environment and women's pocketbooks. With the introduction of its revolutionary menstrual cup The DivaCup in 2003, the company has continued its commitment to this philosophy. The DivaCup was designed by women for women with a vision for a healthy and more sustainable feminine hygiene product. Many tampons and pads are made from a combination of rayon or cotton, which may still con- tain traces of dioxin, a toxic chemical with an adverse reaction to both the environment and health. Unlike tam- pons and pads, The DivaCup is made of 100 percent health-care grade silicone and is free of chemicals, plastics and dyes. Because it is reusable and replaced annually, The DivaCup reduces landfill waste and also helps women save money. The DivaCup also offers women more convenience, confidence and flexi- bility. Easy-to-use and comfortable, The DivaCup provides up to 12 hours of leak- free protection all day and overnight, making it a perfect choice for any activi- ty. With two model options, The DivaCup is ideal for any age. While menstrual cups have been around for more than 80 years, they are making a comeback and are becoming more readily available at mass retailers, along with specialty and natural stores. Women are looking first and foremost for leakage protection and products that are better for their bodies and the envi- ronment, while meeting the demands of their busy lifestyles. Retail partners who sell The DivaCup are satisfying growing con- sumer demand while positioning them- selves as innovators and leaders in the feminine hygiene category. Sales of The DivaCup in dollars and units are growing at double-digit rates, thus contributing real growth to the category. For retailers, the brand generates higher sales dollars and high- er profit margins than traditional femi- nine hygiene products. The DivaCup also delivers higher dollar spend from each consumer, capturing an entire year's worth of spend from each cus- tomer. These retailers also generate higher sales and higher profits for their business. To build consumer awareness and satisfy growing con- sumer demand for both The DivaCup and The DivaWash, Diva International Inc. has planned its most robust advertising plan for 2015, with a planned marketing spend of $3 MM, allocated to television (conventional and specialty), print advertising, digital advertising, social media, public relations and educa- tion. Diva International will also contin- ue retailer-specific "geo-targeted" adver- tising to drive customers to participating retailers. As more and more women move to more natural and alternative solutions, Diva International Inc. and its partners will continue to grow and thrive. Visit Diva International Inc. at booth #1547. For more information, go to www.divacup.com, call 519.896.8100 or email sales@divacup.com. MALLINCKRODT: A STRATEGIC PARTNER IN SPECIALTY GENERICS An interview with Walt Kaczmarek, President, Multisource Pharmaceuticals. CDD: What is Mallinckrodt's approach to its Specialty Generics portfolio? WK: We view our role as a strategic partner. Our goal is to stay customer-cen- tric and demonstrate the value we can bring to a client relationship in addition to competitive pricing. For example, we provide a personalized and connected customer service experience through cus- tomized programs and collaboration, training and resources, enhanced cus- tomer service and external education pro- grams. It is important to be responsive to customer feedback and marketplace needs. CDD: How is Mallinckrodt able to adapt and respond to a changing marketplace? WK: Our experience and our ability to manage the complexities of change both serve us well. We have a more than 20- year history of success in specialty gener- ic product launches, dating back to 1995. Our eight top generic products each hold a top-three position in U.S. market share for their respective categories, and more than 60 million prescriptions are filled per year with Mallinckrodt specialty generic products. We hold a strong posi- tion in the U.S. controlled substances generics market, where we have expert- ise. Mallinckrodt also has a well-respect- ed addiction treatment product line, pro- viding value-added educational support to clinics. CDD: What do you see as important issues emerging in the generic drug mar- ket? WK: More and more there are increasing concerns about rising healthcare costs. Generic medicines play a significant role in slowing down healthcare spend- ing, according to the Generic Pharmaceutical Association's 2014 "Drug Savings in the U.S." report. The report notes that greater reliance on generic med- ication by patients and payors saved the U.S. health system $239 billion in 2013 – an increase in prior year savings by 14 percent – and generic prod- ucts have saved nearly $1.5 trillion in the 10 years from 2004 to 2013. Both new and established generic products con- tributed to these savings, and we believe that generic medicines will continue to provide value in the future. CDD: What is Mallinckrodt's take on the abuse of opioids and prescription drugs? WK: Mallinckrodt is dedicated to pro- viding safe and effective medications for the treatment of patients with pain and is equally committed to working with poli- cymakers, law enforcement and industry to address the complex issues of opioid addiction and abuse. We address diver- sion and abuse through a multidimen- sional approach that includes opioid edu- cational efforts, monitoring for suspicious orders of controlled substances, drug take-back pro- grams and research into abuse- deterrent technologies. CDD: Is Mallinckrodt doing any- thing else to address this issue? WK: Mallinckrodt is a founding sponsor of the Alliance for Balanced Pain Management, a diverse collective of healthcare advocacy groups, patient organizations and industry representa- tives that support both appropriate access to integrated pain management and responsible use of prescription medicines with an aim to reduce abuse and enhance patient safety. The National Association of Chain Drug Stores joined the alliance this past May. Formed in November 2014, the alliance is advancing tools and insights toward shared objectives. Member organizations and resources can be found at www.alliancebpm.org. Visit Mallinckrodt at booth #115. For more information, call 800.325.8888 or go to www.mallinckrodt.com. MARKETOUCH MEDIA'S CLINICAL SOLUTIONS DRIVE PHARMACY PROFITS Pharmacies face unprecedented chal- lenges, including lower profit-per-script from mushrooming generic use and lower margins from the proliferation of closed and limited networks. Pharmacies also recognize that providing higher lev- els of care for at-risk patients (interven- tions, specialty pharmacy, medication therapy management, disease state man- agement, etc.) allows them to adapt and thrive in this changing environment. But success in this arena requires efficient, yet high-touch patient communications. This is why more pharmacies are turning to MarkeTouch Media's suite of full- service clinical solutions. MarkeTouch Media's clinical serv- ice suite empowers clients to more effec- tively manage specific, disease-related patient populations. In addition to deliv- ering better clinical outcomes, MarkeTouch Media's clinical solutions reduce overall healthcare costs and max- imize ROI. For example, its outbound communication solutions have reduced returned-to-stock prescriptions by an average of 40 percent, increasing prof- itability by $600,000 for every million prescriptions filled. The suite also enables users to easily document the information required for prompt and complete payment. RxTouch SM Optimum MedSync is MarkeTouch Media's medication syn- chronization service, which allows patients with multiple medications to move to a common refill date, improving patient adherence, compliance and persistency. Fully cus- tomizable, it allows phar- macists to have targeted, clinical con- versations with their patients while eas- ing the workflow burden on pharmacy staff. Optimum MedSync improves the quality metrics measured by health plans, resulting in additional access to patient lives. It also drives the pharma- cy's bottom line, potentially increasing revenue by more than $1 million in the first year. (Based on 10,000 patients enrolled in the service, with an average of four prescriptions per patient synced to a common refill date.) RxTouch Pharmacist Connect is a fully hosted solution that allows phar- macy staff to efficiently make live, one- on-one patient calls. The service streamlines pharmacy operations and allows each patient to choose their pre- ferred communication channels for pharmacy interaction. By employing the patients' channel prefer- ences, the pharmacy can achieve greater adher- ence and persistency to the prescribed regimen. Each client has the ability to select targeted campaigns that ensure patients make a positive impact on quality and operational metrics. MarkeTouch Media's Clinical Solutions provide guidance on which interventions to apply to specific patients to drive revenues from other sources in the health care environment, including medication therapy management providers, employer groups and other stakeholders. Its data analytics allows customizable, actions-based reporting that drills down to the patient and pre- scription level, showing the impact of interventions applied. Visit MarkeTouch Media at booth #1414 or online at www.rxtouch.com.